Harnessing the Cancer Radiation Therapy by Lanthanide-Doped Zinc Oxide Based Theranostic Nanoparticles
Source abstract
Abstract
In this paper, doping of europium (Eu) and gadolinium (Gd) as high-Z elements into zinc oxide (ZnO) nanoparticles (NPs) was designed to optimize restricted energy absorption from a conventional radiation therapy by X-ray. Gd/Eu-doped ZnO NPs with a size of 9 nm were synthesized by a chemical precipitation method. The cytotoxic effects of Eu/Gd-doped ZnO NPs were determined using MTT assay in L929, HeLa, and PC3 cell lines under dark conditions as well as exposure to ultraviolet, X-ray, and γ radiation. Doped NPs at 20 μg/mL concentration under an X-ray dose of 2 Gy were as efficient as 6 Gy X-ray radiation on untreated cells. It is thus suggested that the doped NPs may be used as photoinducers to increase the efficacy of X-rays within the cells, consequently, cancer cell death. The doped NPs also could reduce the received dose by normal cells around the tumor. Additionally, we evaluated the diagnostic efficacy of doped NPs as CT/MRI nanoprobes. Results showed an efficient theranostic nanoparticulate system for simultaneous CT/MR imaging and cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Radiation Therapy and Dosimetry · Luminescence Properties of Advanced Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Bioengineering, School of Life Sciences, École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland
Department of Materials, University of Oxford, Oxford OX1 3PH, U.K.
Funding
Tehran University of Medical Sciences and Health Services
References (70)
Show source-provided references
1. 10.3322/caac.2120810.3322/caac.21208 ↗
2. Group, E. B. C. T. C. · Lancet · 2006 · 366 · 2087
3. 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-210.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2 ↗
4. 10.1016/S0140-6736(98)05180-010.1016/S0140-6736(98)05180-0 ↗
5. 10.1002/smll.20140120910.1002/smll.201401209 ↗
6. 10.15171/bi.2014.00810.15171/bi.2014.008 ↗
7. 10.1021/nl901610f10.1021/nl901610f ↗
8. Vrouenraets M. B. · Anticancer Res. · 2002 · 23 · 505
9. 10.1016/j.solmat.2005.02.01410.1016/j.solmat.2005.02.014 ↗
10. Fairchild R. · Strahlentherapie · 1984 · 160 · 758
11. 10.1166/jbn.2014.195410.1166/jbn.2014.1954 ↗
12. 10.1016/j.biomaterials.2011.07.03610.1016/j.biomaterials.2011.07.036 ↗
13. 10.3109/17435390.2011.62071710.3109/17435390.2011.620717 ↗
14. 10.1038/nrclinonc.2014.8210.1038/nrclinonc.2014.82 ↗
15. 10.1016/j.biomaterials.2010.10.02210.1016/j.biomaterials.2010.10.022 ↗
16. 10.1039/C4RA08100E10.1039/C4RA08100E ↗
17. He X. · Nature · 2013 · 1 · 30
18. 10.3858/emm.2010.42.2.01610.3858/emm.2010.42.2.016 ↗
19. Carter W. · J. Leukocyte Biol. · 1994 · 55 · 25310.1002/jlb.55.2.253 ↗
20. 10.1016/j.jphotobiol.2014.04.00610.1016/j.jphotobiol.2014.04.006 ↗
21. 10.1016/j.nano.2011.08.00310.1016/j.nano.2011.08.003 ↗
22. 10.1039/C4TB01661K10.1039/C4TB01661K ↗
23. 10.1021/ja068161b10.1021/ja068161b ↗
24. 10.1021/ja027947g10.1021/ja027947g ↗
25. 10.1016/j.jlumin.2009.03.02710.1016/j.jlumin.2009.03.027 ↗
26. 10.1007/s12274-011-0160-710.1007/s12274-011-0160-7 ↗
27. 10.1021/jp980730h10.1021/jp980730h ↗
28. 10.1021/nl061025k10.1021/nl061025k ↗
29. 10.1007/s10495-012-0705-610.1007/s10495-012-0705-6 ↗
30. 10.1517/17425247.2010.50256010.1517/17425247.2010.502560 ↗
31. 10.1089/ars.2006.8.137310.1089/ars.2006.8.1373 ↗
32. 10.1016/j.jphotobiol.2008.07.00910.1016/j.jphotobiol.2008.07.009 ↗
33. 10.1016/j.solmat.2005.02.01410.1016/j.solmat.2005.02.014 ↗
34. Hainfeld J. F. · Cancer Res. · 2005 · 65 · 287
35. Leach J. K. · Cancer Res. · 2001 · 61 · 3894
36. 10.1021/nn406184r10.1021/nn406184r ↗
37. 10.1021/am503622510.1021/am5036225 ↗
38. 10.5402/2012/37250510.5402/2012/372505 ↗
39. 10.1088/0957-4484/19/29/29510310.1088/0957-4484/19/29/295103 ↗
40. 10.1016/j.nano.2010.10.00110.1016/j.nano.2010.10.001 ↗
41. 10.2147/IJN.S2912910.2147/IJN.S29129 ↗
42. Rich I. N. · Blood · 2000 · 95 · 142710.1182/blood.V95.4.1427.004k48_1427_1434 ↗
43. 10.1038/bjc.1980.2010.1038/bjc.1980.20 ↗
44. 10.1093/nar/gku139810.1093/nar/gku1398 ↗
45. 10.1016/j.canlet.2011.12.01210.1016/j.canlet.2011.12.012 ↗
46. 10.1002/ijc.2605410.1002/ijc.26054 ↗
47. Gulia S. · Adv. Mater. Lett. · 2013 · 4 · 87610.5185/amlett.2013.3440 ↗
48. 10.1038/srep0825210.1038/srep08252 ↗
49. 10.1161/01.ATV.0000142810.27849.8f10.1161/01.ATV.0000142810.27849.8f ↗
50. 10.1046/j.1365-201x.1999.00618.x10.1046/j.1365-201x.1999.00618.x ↗
51. 10.1080/09553009914080710.1080/095530099140807 ↗
52. 10.1016/j.mrfmmm.2007.12.01010.1016/j.mrfmmm.2007.12.010 ↗
53. 10.1021/cm047891k10.1021/cm047891k ↗
54. Jie, C.; Wilson, R.Targetted Nanoparticles for Cancer Diagnosis and Treatment. U.S. Patent 0,034,735, 2010.
55. 10.1088/0957-4484/19/29/29510410.1088/0957-4484/19/29/295104 ↗
56. 10.1038/nnano.2015.1710.1038/nnano.2015.17 ↗
57. 10.1021/nn405977t10.1021/nn405977t ↗
58. 10.1021/ac500644x10.1021/ac500644x ↗
59. 10.1021/nn504170x10.1021/nn504170x ↗
60. 10.1021/am502282f10.1021/am502282f ↗
61. 10.1002/adma.20130501810.1002/adma.201305018 ↗
62. 10.1186/s12645-014-0004-810.1186/s12645-014-0004-8 ↗
63. 10.1002/adhm.20120003210.1002/adhm.201200032 ↗
64. 10.1021/ja071471p10.1021/ja071471p ↗
65. 10.1038/nmat157110.1038/nmat1571 ↗
66. 10.1038/srep0365310.1038/srep03653 ↗
67. 10.1021/ja078176p10.1021/ja078176p ↗
68. 10.1002/smll.20130337210.1002/smll.201303372 ↗
69. 10.1002/smll.20150085610.1002/smll.201500856 ↗
70. 10.1002/adhm.20120002810.1002/adhm.201200028 ↗